Dihong Tang
Overview
Explore the profile of Dihong Tang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peng Y, Yang J, Ao J, Li Y, Shen J, He X, et al.
Elife
. 2025 Mar;
13.
PMID: 40066698
Background: Cervical adenocarcinoma (ADC) is more aggressive compared to other types of cervical cancer (CC), such as squamous cell carcinoma (SCC). The tumor immune microenvironment (TIME) and tumor heterogeneity are...
2.
Li L, Cheng H, Peng Y, Tang D
Biochem Genet
. 2024 Oct;
PMID: 39438390
Cisplatin (DDP) resistance is one of the causes of treatment failure for ovarian cancer (OV). Mitochondrial cholesterol level was reported to be associated with OV chemoresistance. We found that ABCA10,...
3.
Fang C, Zhou Y, Feng Y, He L, Yu J, Li Y, et al.
J Gynecol Oncol
. 2024 Apr;
35(6):e77.
PMID: 38606822
Objective: QL1604 is a highly selective, humanized monoclonal antibody against programmed death protein 1. We assessed the efficacy and safety of QL1604 plus chemotherapy as first-line treatment in patients with...
4.
Feng X, Meng X, Tang D, Guo S, Liao Q, Chen J, et al.
Cancer Pathog Ther
. 2024 Feb;
2(1):38-49.
PMID: 38328710
Background: Immunotherapy favors patients with tumors; however, only 3-26.3% of patients with cervical cancer benefit from single-agent immune checkpoint inhibitors. Combined immunotherapy and chemotherapy has been explored against tumor; however,...
5.
Feng J, Tang D, Wang J, Zhou Q, Peng J, Lou H, et al.
Clin Cancer Res
. 2022 Jun;
28(24):5297-5305.
PMID: 35653122
Purpose: Patients with recurrent or metastatic cervical cancer have limited treatment options after platinum-containing treatment. We initiated a phase I study to assess SHR-1701, a novel bifunctional fusion protein composed...
6.
Gao J, Yang T, Wang X, Zhang Y, Wang J, Zhang B, et al.
Cancer Cell Int
. 2021 Mar;
21(1):157.
PMID: 33685462
Background: Uterine leiomyosarcoma (ULMS) is a malignant tumor found in the smooth muscle lining the walls of the uterus. Cancer stem cells (CSCs) are responsible for metastasis, drug resistance, and...
7.
Peng Y, Tang D, Zhao M, Kajiyama H, Kikkawa F, Kondo Y
Cancer Metastasis Rev
. 2020 Jun;
39(3):825-835.
PMID: 32594276
Chemotherapy is one of the important and effective options for cancer treatment in the past decades. Although the response rate of initial chemotherapy is considerably high in certain types of...
8.
Li Y, Tang D, Zhu L, Cai J, Chu C, Wang J, et al.
Anal Biochem
. 2019 Aug;
585:113346.
PMID: 31401004
The variations in microRNA (miRNA) expression levels can be useful biomarkers for the diagnosis of different cancers. In this work, a label-free and sensitive fluorescent method for detection of miRNA-21...
9.
Zhu L, Tu H, Liang Y, Tang D
World J Surg Oncol
. 2018 Oct;
16(1):204.
PMID: 30314496
Background: As indoleamine-2,3-dioxygenase 1 (IDO1) is critical in tumor immune escape, we determined to study the regulatory mechanism of miR-218 on IDO1 in cervical cancer. Methods: Real-time PCR (RT-qPCR) was...
10.
Cai J, Peng T, Wang J, Zhang J, Hu H, Tang D, et al.
Cell Physiol Biochem
. 2016 Sep;
39(4):1421-32.
PMID: 27606814
Background/aims: Cancer stem cells (CSCs) exhibit enhanced proliferative capacity and resistance to chemotherapy; however, choriocarcinoma CSCs have not yet been reported. In this study the human choriocarcinoma cell line JEG-3...